Drugs / Nanocolloid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04487912 Comparator | Nov 2020 → May 2021 | breast cancer | University Hospital, Ghent | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanocolloid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04487912 ↗ |
| Modality | Diagnostic / imaging agent | “the standard used tracer (nanocolloid) to determine whether there is a significant difference between both products” NCT04487912 ↗ |
| Route | Other | “Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid” NCT04487912 ↗ |